RGC | Regencell Bioscience Holdings Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	21.00 - 39.51
52 Week Range	3.03 - 69.00
Beta	N/A
Implied Volatility	16.03%
IV Rank	42.07%
Day's Volume	425,759
Average Volume	683,271
Shares Outstanding	13,012,900
Market Cap	414,851,252
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2021-07-16

Valuation
Profitability
Growth
Health
P/E Ratio	-96.61
Forward P/E Ratio	N/A
EPS	-0.33
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	12
Country	Hong Kong
Website	RGC

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

RGC's peers: BFRI, COLL, CPIX, EVO, EVOK, HCM, INCR, IXHL, OPTN, PBH, PRFX, DLTNF, RAMMF, CVGRF, BHHKF, SPBBF, PROCW, SSIC, EGRX, PAHC, SBFMW, COSM, ACRX, HEXO, ANIP, PROC, RMTI, SUPN, SXTC, TKNO, UPC

*Chart delayed

Analyzing fundamentals for RGC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see RGC Fundamentals page.

Watching at RGC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RGC Technicals page.